Recent efforts have suggested that the β-adrenergic receptor (β–AR) system may be a novel and viable therapeutic target for pain reduction, however most of the work to date has focused on the β2–adrenergic receptor. Here, we compared the antinociceptive effects of enantiomeric configurations of propranolol and bupranolol, two structurally similar non-selective β-blocking drugs against mouse models of inflammatory and chronic pain. In addition, we calculated in silico docking and measured the binding properties of propranolol and bupranolol for all three β–ARs.
from The Journal of Pain http://ift.tt/1Gtu5Le
via IFTTT
No comments:
Post a Comment